不同剂量布地奈德联合孟鲁司特治疗支气管哮喘的疗效对比
|
摘要
目的:探讨不同剂量布地奈德联合孟鲁司特治疗支气管哮喘的疗效。方法:将150例支气管哮喘患者随机分为三组,其中低剂量组(A组)50例,中剂量组(B组)50例,高剂量组(C组)50例,三组患者均给予布地奈德联合孟鲁司特治疗,孟鲁司特剂量均为每晚10 mg,布地奈德剂量分别为A组0.4 mg/次,B组为0.8 mg/次,C组为1.6 mg/次。对比三组患者的临床疗效。结果:C组与B组患者症状与体征消失时间明显早于A组患者,差异有统计学意义(P<0.05),C组患者症状与体征消失时间略晚于B组,差异无统计学意义(P>0.05);治疗后,C组与B组患者肺功能均明显好于B组患者,差异有统计学意义(P<0.05),C组与B组肺功能比较,差异无统计学意义(P>0.05);C组与B组患者炎性因子水平明显低于A组患者,差异有统计学意义(P<0.05),C组与B组炎性因子水平比较,差异无统计学意义;三组患者均未出现明显不良反应。结论:不同剂量的布地奈德联合孟鲁司特均能够改善支气管哮喘患者病情,中等剂量的布地奈德效果最佳,适合用于临床治疗。
Objective To investigate the efficacy of different doses of budesonide combined with montelukast in the treatment of bronchial asthma.Method 150 patients with bronchial asthma were randomly divided into 3 groups,including 50 cases in the low dose group(group A),50 cases in the middle dose group(group B),and 50 patients in the high dose group(group C).3 patients were treated with budesonide combined with montelukast,the dose of montelukast was 10 mg per night,budesonide dose was 0.4 mg/time in group A,0.8 mg/time in group B The C group was 1.6 mg/time.Compare the clinical efficacy of the three groups of patients.Results The disappearance of symptoms and signs in patients with C and B was significantly earlier than that in group A(P<0.05).The disappearance of symptoms and signs in group C was slightly later than that in group B(P>0.05).After treatment,C The lung function of patients with group B was significantly better than that of group B(P<0.05).There was no significant difference in lung function between group C and group B(P>0.05).The levels of inflammatory factors in group C and group B were significantly lower than those in group A(P<0.05),there was no significant difference in the levels of inflammatory factors between group C and group B;all groups of patients had obvious adverse reactions.Conclusion Different doses of budesonide combined with montelukast can improve the condition of patients with bronchial asthma.The medium dose of budesonide is the best and suitable for clinical treatment.
Objective To investigate the efficacy of different doses of budesonide combined with montelukast in the treatment of bronchial asthma.Method 150 patients with bronchial asthma were randomly divided into 3 groups,including 50 cases in the low dose group(group A),50 cases in the middle dose group(group B),and 50 patients in the high dose group(group C).3 patients were treated with budesonide combined with montelukast,the dose of montelukast was 10 mg per night,budesonide dose was 0.4 mg/time in group A,0.8 mg/time in group B The C group was 1.6 mg/time.Compare the clinical efficacy of the three groups of patients.Results The disappearance of symptoms and signs in patients with C and B was significantly earlier than that in group A(P<0.05).The disappearance of symptoms and signs in group C was slightly later than that in group B(P>0.05).After treatment,C The lung function of patients with group B was significantly better than that of group B(P<0.05).There was no significant difference in lung function between group C and group B(P>0.05).The levels of inflammatory factors in group C and group B were significantly lower than those in group A(P<0.05),there was no significant difference in the levels of inflammatory factors between group C and group B;all groups of patients had obvious adverse reactions.Conclusion Different doses of budesonide combined with montelukast can improve the condition of patients with bronchial asthma.The medium dose of budesonide is the best and suitable for clinical treatment.
引文
[1] 吴海丽,李贤斌.气雾型布地奈德联合孟鲁司特钠治疗小儿咳嗽变异性哮喘疗效及对肺功能和血清炎症因子的影响[J].海南医学院学报,2016,22(5):467.
[2] 汤建梅.孟鲁司特钠联合布地奈德对咳嗽变异性哮喘患儿血清免疫球蛋白E、白细胞介素-4及转化生长因子-β_1水平的影响[J].吉林医学,2017,38(3):520.
[3] 张媛,张铁栓.孟鲁司特联合布地奈德治疗嗜酸粒细胞性支气管炎的疗效及预防复发作用[J].实用医学杂志,2016,32(1):121.
[4] 张佳佳,胡赤军,周小勤,等.布地奈德联合孟鲁司特钠对支气管哮喘患儿细胞因子、免疫功能影响[J].现代生物医学进展,2017,17(3):550.
[5] 莫丽慧,钟丽花.孟鲁司特联合布地奈德治疗支气管哮喘患儿的临床观察[J].中国药房,2017,28(14):1981.
[6] 许志伟,贝为豪,刘沛.孟鲁司特钠联合阿奇霉素治疗小儿喘息性支气管炎疗效观察[J].吉林医学,2017,38(3):413.
[7] Scichilone N,Braido F,Lavorini F,et al.Routine Use of Budesonide/Formoterol Fixed Dose Combination in Elderly Asthmatic Patients:Practical Considerations[J].Drugs & Aging,2017,34(35):1.
[8] 管锡富.布地奈德雾化吸入联合孟鲁司特治疗小儿哮喘急性发作的疗效观察[J].中国妇幼保健,2017,21(4):759.
[9] Singh A,Nandan D,Dewan V,et al.Comparison of clinical effects of beclomethasone dipropionate & budesonide in treatment of children with mild persistent asthma:A double-blind,randomized,controlled study[J].Indian Journal of Medical Research,2016,144(2):250.
[10] 郭鹏.布地奈德与孟鲁司特对支气管哮喘患儿临床症状和气道炎症的影响[J].安徽医药,2017,21(10):1861.
[11] Lun X,Wells J C,Grinshtein N,et al.Disulfiram when Combined with Copper Enhances the Therapeutic Effects of Temozolomide for the Treatment of Glioblastoma[J].Clinical Cancer Research,2016,22(15):3860.
[12] 吴玲玲.布地奈德吸入联合孟鲁司特钠对小儿哮喘疗效及炎症因子的影响[J].中国妇幼保健,2017,32(1):191.
[2] 汤建梅.孟鲁司特钠联合布地奈德对咳嗽变异性哮喘患儿血清免疫球蛋白E、白细胞介素-4及转化生长因子-β_1水平的影响[J].吉林医学,2017,38(3):520.
[3] 张媛,张铁栓.孟鲁司特联合布地奈德治疗嗜酸粒细胞性支气管炎的疗效及预防复发作用[J].实用医学杂志,2016,32(1):121.
[4] 张佳佳,胡赤军,周小勤,等.布地奈德联合孟鲁司特钠对支气管哮喘患儿细胞因子、免疫功能影响[J].现代生物医学进展,2017,17(3):550.
[5] 莫丽慧,钟丽花.孟鲁司特联合布地奈德治疗支气管哮喘患儿的临床观察[J].中国药房,2017,28(14):1981.
[6] 许志伟,贝为豪,刘沛.孟鲁司特钠联合阿奇霉素治疗小儿喘息性支气管炎疗效观察[J].吉林医学,2017,38(3):413.
[7] Scichilone N,Braido F,Lavorini F,et al.Routine Use of Budesonide/Formoterol Fixed Dose Combination in Elderly Asthmatic Patients:Practical Considerations[J].Drugs & Aging,2017,34(35):1.
[8] 管锡富.布地奈德雾化吸入联合孟鲁司特治疗小儿哮喘急性发作的疗效观察[J].中国妇幼保健,2017,21(4):759.
[9] Singh A,Nandan D,Dewan V,et al.Comparison of clinical effects of beclomethasone dipropionate & budesonide in treatment of children with mild persistent asthma:A double-blind,randomized,controlled study[J].Indian Journal of Medical Research,2016,144(2):250.
[10] 郭鹏.布地奈德与孟鲁司特对支气管哮喘患儿临床症状和气道炎症的影响[J].安徽医药,2017,21(10):1861.
[11] Lun X,Wells J C,Grinshtein N,et al.Disulfiram when Combined with Copper Enhances the Therapeutic Effects of Temozolomide for the Treatment of Glioblastoma[J].Clinical Cancer Research,2016,22(15):3860.
[12] 吴玲玲.布地奈德吸入联合孟鲁司特钠对小儿哮喘疗效及炎症因子的影响[J].中国妇幼保健,2017,32(1):191.